ENTRY       D10588            Mixture   Drug
NAME        Empagliflozin and linagliptin;
            Glyxambi (TN)
PRODUCT     GLYXAMBI (Boehringer Ingelheim Pharmaceuticals)
COMPONENT   Empagliflozin [DR:D10459], Linagliptin [DR:D09566]
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
            Transporter substrate
             DG01665  ABCB1 substrate
             DG01913  ABCG2 substrate
REMARK      Therapeutic category: 3969
            ATC code: A10BD19
            Product: D10588<JP/US>
EFFICACY    Antidiabetic
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
COMMENT     Empagliflozin is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
METABOLISM  Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BD Combinations of oral blood glucose lowering drugs
                 A10BD19 Linagliptin and empagliflozin
                  D10588  Empagliflozin and linagliptin &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Combinations
               Empagliflozin/ Linagliptin
                D10588  Empagliflozin and linagliptin
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               396  Antidiabetic agents
                3969  Others
                 D10588  Empagliflozin and linagliptin
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG03035  Combination of DPP-4 inhibitor and SGLT2 inhibitor
                D10588  Empagliflozin and linagliptin
             Transporter substrate
              DG01665  ABCB1 substrate
               D10588  Empagliflozin and linagliptin
              DG01913  ABCG2 substrate
               D10588  Empagliflozin and linagliptin
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               D10588  Empagliflozin and linagliptin
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10588
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug transporters
              D10588
DBLINKS     PubChem: 254741550
///
